---
title: "Management of Parkinson's disease if levodopa is broken down prematurely"
euct_id: 2024-510629-24-00
phase: Phase 4
status: Recruiting
sponsor: Stichting Radboud University Medical Center
canonical_url: "https://parkinsonspathways.com/trials/eu/2024-510629-24-00"
eu_clinical_trials_register: "https://euclinicaltrials.eu/ctis-public/view/2024-510629-24-00"
ctis_last_updated: "2026-02-05T02:39:24.149054565"
source: EU Clinical Trials Information System (CTIS)
---
# Management of Parkinson's disease if levodopa is broken down prematurely

**EU CT Number:** [2024-510629-24-00](https://euclinicaltrials.eu/ctis-public/view/2024-510629-24-00)

## Key Facts

- **Phase:** Phase 4
- **Status:** Recruiting
- **Sponsor:** Stichting Radboud University Medical Center
- **Start Date:** 2024-12-01
- **Completion Date:** 2027-08-01
- **Conditions:** Parkinson's disease
- **Interventions:** Domperidon Accord 10 mg, tabletten, XIFAXAN 550 mg filmomhulde tabletten, Dacepton 10 mg/ml oplossing voor injectie in een patroon, Placebo capsules, Madopar 125 mg, dispergeerbare tabletten

## Member States

Trial is authorized in 1 member state: Netherlands.

## Sites (1)

- Radboud universitair medisch centrum Stichting, Nijmegen, Netherlands

## Eligibility (CTIS)

- **Minimum age:** 18 Years
- **Sex:** ALL

```
Condition: Parkinson's disease
Age groups: adults 18-64, elderly 65+
Sex: male, female
```

---

*Canonical: https://parkinsonspathways.com/trials/eu/2024-510629-24-00*  
*HTML version: https://parkinsonspathways.com/trials/eu/2024-510629-24-00*  
*Source data: https://euclinicaltrials.eu/ctis-public/view/2024-510629-24-00*